Sign in

Gregory J. Divis

Chief Executive Officer and Director at AVADEL PHARMACEUTICALS
Board
Since June 2019
Age
58 years
Education
Earned a B.S. (Bachelor of Science) degree from the University of Iowa.
Tenure
Joined Avadel Pharmaceuticals in January 2017 as Executive Vice President and Chief Commercial Officer, was promoted to Chief Operating Officer in March 2018, served as Interim CEO in January 2019, and was appointed as Chief Executive Officer and Director in June 2019.

Also at AVADEL PHARMACEUTICALS

JGS
Jerad G. Seurer
General Counsel and Corporate Secretary
RJK
Richard J. Kim
Chief Commercial Officer
TSM
Thomas S. McHugh
Chief Financial Officer

About

Gregory J. Divis, born in 1967 and 58 years old as of March 2025 , has developed a robust career in the pharmaceutical industry over the past 25 years. He is a graduate of the University of Iowa, where he earned his B.S. degree, laying the foundation for his professional journey.

Before joining Avadel Pharmaceuticals, Divis held several prominent roles in the industry. He served as President and Chief Executive Officer of Lumara Health (formerly K-V Pharmaceutical Company), contributed as President of Ther-Rx Corporation, and held significant roles at Sanofi-Aventis and Schering-Plough Corporation. His early career also included a stint as an Executive-in-Residence at Linden Capital Partners, demonstrating his versatility and depth in healthcare business operations.

At Avadel Pharmaceuticals, his trajectory has been marked by rapid progression. He joined the company in January 2017 as Executive Vice President and Chief Commercial Officer, was elevated to Chief Operating Officer in March 2018, and then served as Interim CEO in January 2019 before taking on the current position as Chief Executive Officer and Director in June 2019.

Under his leadership, the company has benefited from his extensive expertise in strategic operations and commercial strategy, driving growth and positioning Avadel strongly within the competitive pharmaceutical sector.

$AVDL Performance Under Gregory J. Divis

Past Roles

Organization Role Date Range Details
Avadel Pharmaceuticals (AVDL) Executive Vice President and Chief Commercial Officer January 2017 – March 2018 Managed commercial strategy and execution; ended with promotion
Avadel Pharmaceuticals (AVDL) Chief Operating Officer March 2018 – January 2019 Oversaw commercial strategy and operations; transitioned to interim CEO
Avadel Pharmaceuticals (AVDL) Interim Chief Executive Officer January 2019 – May 2019 Served as interim CEO prior to his permanent appointment as CEO
Linden Capital Partners Operating Partner / Executive-in-Residence June 2015 – December 2016 Middle-market healthcare-focused private equity firm role
K-V Pharmaceutical Company / Lumara Health President and Chief Executive Officer May 2010 – November 2014 Led the company through Chapter 11 bankruptcy filing on August 4, 2012, emergence on September 16, 2013, and acquisition by AMAG Pharmaceuticals in November 2014
Ther-Rx Corporation President N/A Subsidiary of K-V Pharmaceutical Company
Sanofi-Aventis Vice-President, Business Development & Lifecycle Management N/A N/A
Schering-Plough Corporation Vice-President and General Manager, UK and Ireland N/A N/A

External Roles

Organization Role Date Range Details
Jaguar Health, Inc. Board of Directors Current Publicly traded pharmaceutical company

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$600,000 AnnualFixed annual base salary
All Other Compensation$25,200 AnnualIncludes Employer 401(k) Contributions: $13,200 and Auto Allowance: $12,000

Performance Compensation

Data from  FY 2023

Annual Cash Incentive Award for 2023

MetricValueDetails
Performance MetricsCorporate performance goals Includes achieving LUMRYZ launch revenue and patient demand targets, meeting operating expense and cash balance targets
Target Bonus$360,000 60% of the base salary ($600,000)
Actual Awarded$360,000 Fully awarded based on a 100% corporate performance score
Vesting ScheduleN/ANo vesting; bonus is paid out annually based on performance
Evaluation PeriodCalendar Year 2023 Performance evaluated over the full year 2023

Equity Awards (Performance Share Units) for 2023

MetricValueDetails
PSU Target175,000 PSUs Target number of performance share units awarded
Performance MetricsCorporate objectives Based on achieving corporate objectives including exceeding revenue and patient demand forecasts
Vesting ScheduleOne-third H2 2023; Two-thirds Calendar Year 2024 Vesting is split between performance in the second half of 2023 and the entirety of calendar year 2024
Grant Date / Fair Value / Stock PriceN/ANot applicable as grant date not set for accounting purposes due to discretionary performance criteria
Threshold/Target/WeightsN/ASpecific thresholds or weightings were not disclosed